

IMPLEMENTATION SCIENCE MODELS (AND RELATED METRICS) TO HELP REDUCE HEALTH DISPARITIES

Russell E. Glasgow, Ph.D.

Deputy Director,
Implementation Science
Division of Cancer Control and
Population Sciences
National Cancer Institute

OUTLINE

- Implementation Science (IS) Models-overview
- RE-AIM Model—and metrics
- Evidence Integration Triangle (EIT)
- Commonalities and Conclusions

Implementation Science Frameworks: Converging Recommendations

- Recent review of Implementation Science Models (Tabak RG, et al. Am J Prev Med 2012;43:337-50)
- RE-AIM: Reach, Effectiveness, Adoption, Implementation and Maintenance—the "What" www.re-aim.org
- Evidence Integration Triangle (EIT)—the "How" http://cancercontrol.cancer.gov/IS/presentations.html



Implementation and Dissemination Research Characteristics (Russ' view)

- Contextual
- Complex
- Multi-component programs and policies
- Non-linear
- Transdisciplinary
- Multi-level
- Addresses "wicked", messy, important problems


Glasgow RE, Steiner JF In: Brownson RC, Colditz G, Proctor E, eds. Dissemination and implementation research in health: Translating science and practice. New York: Oxford University Press, 2012:72-93.





THE SAME POLICIES, RESEARCH METHODS, PARADIGMS AND APPROACHES THAT PRODUCED TODAY'S INEQUITIES ARE NOT LIKELY TO REDUCE THEM

"The significant problems we face cannot be solved by the same level of thinking that created them."



A. Einstein




Recommended Purpose of Research (ala RE-AIM—www.re-aim.org)

Collect evidence to document interventions that can:

- Reach large numbers of people, especially those who can most benefit
- Be widely <u>adopted</u> by different settings
- Be consistently <u>implemented</u> by staff members with moderate levels of training and expertise
- Produce <u>replicable</u> and <u>maintained effects</u> (and minimal negative impacts) at reasonable <u>cost</u>

Gaglio B, Glasgow RE. In: Brownson R, Colditz G, Proctor E, eds. Dissemination and implementation research in health: Translating science to practice. New York: Oxford University Press, 2012:327-56



RE-AIM—Disparities Implications

RE-AIM Element	
Reach	 Characteristics of those who participate vs. decline Expand categories used for classification of potential disparities- e.g. literacy, numeracy, address, geospatial
Effectiveness	"Representative narrative"Impact of contextUnanticipated consequences
Adoption	 Engage stakeholders from low resource settings from outset Document and address reasons for non-participation
Implementation	Monitor DeliveryTrack costs of implementationBe transparent
Maintenance	 Assess long-term results of different subgroupsIf inequities, find out why Prepare delivery settings with tools to guide, monitor and adapt intervention Support and study sustainability



RE-AIM—Disparities Implications Continued

RE-AIM Issue	<u>Disparity</u>	<u>Overall Impact</u>
Reach	30%	70% of benefit
Effectiveness	0 (equal)	70% of benefit
Adoption	30%	49% of benefit
Implementation	30%	34% of benefit
Maintenance	30%	24% of benefit




RE-AIM Implications— What Outcomes and Metrics are Valuable?

- Beyond Mean Effect Size?
- Ask- at multiple levels WHO is reached, WHAT type settings are implementing; WHICH staff can implement, etc.
- All 5 RE-AIM dimensions are important—need to broaden usual focus

RE-AIM Self-Rating Quiz

http://re-aim.org/resources_and_tools/index.html







Evidence Integration Triangle (EIT)

Intervention Program/Policy (Prevention or Treatment)

(e.g., key components; principles; guidebook; internal & external validity)



Participatory Implementation Process

(e.g., stakeholder engagement; CBPR; team-based science; patient centered)



Practical Progress Measures

(e.g., actionable & longitudinal measures)

Multi-Level Context

- Intrapersonal/Biological
- Interpersonal/Family
- Organizational

- Policy
- Community/Economic
- Social/Environment/History

Glasgow RE, Green LW, Taylor MV, et al. Am J Prev Med 2012;42:646-54

IMPLICATIONS OF EIT FOR REDUCING DISPARITIES


- Evidence alone is a start, but not enough
- Need relevant, practical Measures and Metrics of progress
- Both of above need to be selected with partnership of stakeholders
- Expect iteration and adaptation—rather than immediate success



QUESTIONS TO ASK....

- In this world of "the 4 P's" of personalized medicine.... ALSO ask the 4 "W's":
 - ✓ Who Benefits
 - ✓ Who Suffers
 - ✓ Who Pays
 - ✓ Who Profits

Glasgow RE, Fisher EB, Haire-Joshu D, Goldstein MG. Am J Public Health 97(11):1936-1938 (Editorial)



TAKE-HOME POINTS

- Start with the End (Dissemination? Scale-Up: Sustainability? Reducing Disparities?) in Mind
- Start with and Partner with Stakeholders Throughout All Phases......
 including Design and Analyses
- Implementation Science is Complex, Dynamic, Contextual, Learning, Systems Based.... and our models, designs and metrics need to be also
- All Models (including these) are WRONG....but may be useful